卡培他滨单药治疗晚期胃肠道肿瘤的临床观察  

Clinical Observation on Capecitabine monotherapy for patients with advanced stomach and colorectal carcinoma

作　　者：杨苏慧 孙建华[2] 张月芬 

机构地区：[1]山西省同煤集团肿瘤专科医院肿瘤科,037003 [2]北京大学首钢医院肿瘤科,100144

出　　处：《内蒙古中医药》2010年第16期82-83,共2页Inner Mongolia Journal of Traditional Chinese Medicine

摘　　要：目的：观察卡培他滨单药治疗晚期胃肠道肿瘤的临床疗效及不良反应。方法：对36例晚期胃肠道肿瘤患者，采用卡培他滨片治疗，2500mg／m^2，每日两次口服，第1—14天，服用两周后休息一周，21天为一个周期，至少两周期评价疗效和不良反应。结果：36例患者治疗后，完全缓解CR2例（5．5％），部分缓解PR15例（41．7％），稳定SD12例（33．3％）进展7例（19．4％），总有效率47．2％。常见不良反应为手足综合征，皮肤色素沉着，恶心呕吐，腹泻，口腔炎，骨髓抑制等，不良反应轻微，多为Ⅰ～Ⅱ级。结论：卡培他滨单药治疗晚期胃肠道肿瘤疗效高，不良反应轻，患者耐受性好。Objectives： To observe the effects and adverse reactions of Capecitabine monotherapy for advanced stomach and colorectal carcinoma. Methods： 36 patients with advanced stomach and colorectal carcinoma were treated with Capecitabine. Capecitabine was given at a dose of 2500 mg/m2, twice daily, and given from dayl to day14, for two weeks followed by one week rest as one cycle. The treatment cycle was every 21 days, at least for two cycles .Results： Among these 36 patients, there were 2 complete response （CR）, Rates of partial response 15 （41.7%）.Stable disease 12, progressive disease 7, overall response-rates （CR＋PR） were 47.2%. Commonly occurring adverse events were hand-foot syndrome, skin pigmentation, nausea and vomiting, diarrhea, oral mucositis, arrest of bone marrow and so on. The adverse reactions were small, they werel^2 grade. Conclusion： Capecitabine monotherapy for the patients with advanced stomach and colorectal carcinoma has better treatment efficacy. The adverse reactions were small, and the patients were tolerant.

关 键 词：卡培他滨 单药治疗 化学治疗 晚期胃肠道肿瘤 

分 类 号：R735[医药卫生—肿瘤]